LTX-315 is a novel broad-spectrum antimicrobial peptide against clinical multidrug-resistant bacteria
The unique mechanism of LTX-315 involves high-affinity binding to PG and subsequent membrane disruption, providing a novel approach against multidrug-resistant bacteria compared to conventional antibiotics. As a potential candidate, it shows promise in effectively treating bacterial infections, particularly those caused by drug-resistant bacteria, thereby addressing the escalating challenge of antibiotic resistance worldwide.
Authors
- Edward Wai‐Chi Chan (ORCID: https://orcid.org/0000-0002-7570-5289)
- Heng Heng (ORCID: https://orcid.org/0000-0003-4722-5816)
- Yang Tang (ORCID: https://orcid.org/0000-0001-7328-7709)
- Liang Dai (ORCID: https://orcid.org/0000-0002-4672-6283)
- Chen Yang (ORCID: https://orcid.org/0000-0001-9876-724X)
- Sheng Chen (ORCID: https://orcid.org/0000-0003-3526-7808)
- Jiamin Zhao (ORCID: https://orcid.org/0000-0001-9335-864X)
- Mingxiu Peng
- Liang Sun (ORCID: https://orcid.org/0000-0002-0034-2567)
Institutions
- Hong Kong Polytechnic University (HK)
- City University of Hong Kong (HK)
- City University of Hong Kong, Shenzhen Research Institute (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.jare.2024.12.044
- Citations
- 9
- Primary Topic
- Antimicrobial Peptides and Activities
- Type
- article
- Field-Weighted Citation Impact
- 10.65
Funders
- Impact Fund
- Hong Kong Government